Literature DB >> 7713101

Dose-response relationships of ACE inhibitors and angiotensin II blockers.

H R Brunner1, J Nussberger, B Waeber.   

Abstract

It is difficult to establish dose-response relationships for ACE inhibitors in patients with hypertension or congestive heart failure. This has led to the widely held opinion that the effects of ACE inhibitors are hardly dose dependent. The purpose of this short discussion is to demonstrate that this class of compounds, as well as the more recent angiotensin II receptor antagonists, exhibit some very clear dose-response relationships when these are evaluated in normal volunteers based on the mechanisms for which they were designed. Characterization of these dose-response curves is important in order to use these drugs at their optimal dose and to obtain the maximal therapeutic benefit.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7713101     DOI: 10.1093/eurheartj/15.suppl_d.123

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  4 in total

Review 1.  Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.

Authors:  C Csajka; T Buclin; H R Brunner; J Biollaz
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

2.  Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system.

Authors:  C Buchwalder-Csajka; T Buclin; H R Brunner; J Biollaz
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

3.  A survey of the dose of ACE inhibitors prescribed by general physicians for patients with heart failure.

Authors:  R McMullan; B Silke
Journal:  Postgrad Med J       Date:  2001-12       Impact factor: 2.401

4.  Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis.

Authors:  N Girgrah; P Liu; J Collier; L Blendis; F Wong
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.